The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 55 | — | 20.1x | Near average | |
Growth | 46 | 10.9% | 5.6% | Near average | |
Quality | 31 | -17.0% | 7.6% | Below average | |
Safety | 25 | 4.0x | 0.4x | Below average | |
Capital Return | 41 | — | 2.19% | Near average | |
Momentum | — | — | — | No data | |
Sentiment | — | — | — | No data |
NeoGenomics, Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy NeoGenomics, Inc. shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
The analyst forecast analysis for NeoGenomics shows complete stability in the target price at 19 dollars over the past 7 and 30-day periods, with a consensus from only 3 analysts. Despite the stability in the target, there is a wide gap (Dispersion) between the low of 13 dollars and the high of 25 dollars, reflecting a state of uncertainty regarding the company's fair valuation despite the steady average.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.